InvestorsHub Logo
icon url

rayovacAAA

03/17/22 10:56 AM

#354525 RE: kevindenver #354522

HOW IS PDD RELEVANT TO DOSE-DEPENDENCY IN A2-73 RETT TRIAL DATA?????


https://parkinsonsnewstoday.com/2022/03/17/anavex-2-73-high-dose-improves-pdd-patients-subscores-mds-updrs-phase-2-trial-update/

I understand the need to play devil's' advocate, but...I was able to find a statement regarding dose-dependency in PDD.




WE GOT THIS!!!
icon url

frrol

03/17/22 11:02 AM

#354532 RE: kevindenver #354522

Yes, in PDD we're seeing dose dependency signal in the endpoint scores. It's good stuff. We're also seeing dependency on SIGMAR1 status (wt vs mut). I'm hoping we eventually are given SIGMAR1 status analysis for the Rett trials. Would be good to see dependency, since their were apparent non-responders.